Thomas Gad - Dec 13, 2023 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Signature
/s/ Thomas Gad
Stock symbol
YMAB
Transactions as of
Dec 13, 2023
Transactions value $
-$1,001,000
Form type
4
Date filed
12/15/2023, 07:40 PM
Previous filing
Nov 22, 2023
Next filing
Dec 26, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YMAB Common Stock Sale -$329K -50K -12.05% $6.58 365K Dec 13, 2023 By GAD Enterprises LLC F1, F2
transaction YMAB Common Stock Sale -$342K -50K -13.7% $6.83 315K Dec 14, 2023 By GAD Enterprises LLC F2, F3
transaction YMAB Common Stock Sale -$331K -50K -15.87% $6.61 265K Dec 15, 2023 By GAD Enterprises LLC F2, F4
holding YMAB Common Stock 60K Dec 13, 2023 By Children F5
holding YMAB Common Stock 90.5K Dec 13, 2023 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $6.355 to $6.83, inclusive. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 Reporting Person is sole member of GAD Enterprises, LLC and the sole member and manager of GAD Management, LLC, the manager of GAD Enterprises, LLC, and as such Reporting Person has sole voting and dispositive power with respect to such shares.
F3 This transaction was executed in multiple trades at prices ranging from $6.75 to $7.14. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 This transaction was executed in multiple trades at prices ranging from $6.49 to $6.78, inclusive. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 Represents shares owned by Reporting Person's children who are deemed to share Reporting Person's household.
F6 Represents 50,000 shares of Common Stock owned by Reporting Person as well as 40,500 restricted stock units ("RSUs") granted to the Reporting Person on January 17, 2023 pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU. The RSUs vest by 1/3 on each of January 17, 2024, January 17, 2025 and January 17, 2026 subject to the continuing employment of the Reporting Person on each vesting date.